ImmunoGen shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $9 to $20.
Portfolio Pulse from Benzinga Newsdesk
ImmunoGen shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $9 to $20.
June 12, 2023 | 5:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintained an Overweight rating on ImmunoGen and raised its price target from $9 to $20, leading to higher trading.
The news directly mentions ImmunoGen (IMGN) and states that Barclays has maintained an Overweight rating on the stock while raising its price target from $9 to $20. This positive analyst rating and increased price target are likely to boost investor confidence and lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100